Clinical Trials | December 27, 2025
InnoCare Pharma gets green light for Phase II trial of oral lupus drug
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The move strengthens GBL’s clinical-stage presence in the United States
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Subscribe To Our Newsletter & Stay Updated
